NIKKEI 225
39,094.62 +477.52 (+1.24%) HANG SENG
18,908.63 -286.97 (-1.49%) CRUDE OIL
77.05 -0.52 (-0.67%) GOLD FUTURES
2,373.90 -19.00 (-0.79%) DOW
39,671.04 -201.95 (-0.51%) Bitcoin GBP
54,527.84 -265.16 (-0.48%)
Protalix BioTherapeutics, Inc. (PLX)
After hours:
| Previous close | 1.2000 |
| Open | 1.1900 |
| Bid | 0.0000 x 800 |
| Ask | 0.0000 x 800 |
| Day's range | 1.1897 - 1.3500 |
| 52-week range | 1.0300 - 2.5100 |
| Volume | |
| Avg. volume | 433,001 |
| Market cap | 94.578M |
| Beta (5Y monthly) | 0.90 |
| PE ratio (TTM) | 16.12 |
| EPS (TTM) | 0.0800 |
| Earnings date | 05 Aug 2024 - 09 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 12.00 |
- GuruFocus.com
Protalix BioTherapeutics Inc (PLX) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
Despite a dip in revenue, Protalix BioTherapeutics progresses with promising clinical trials and maintains a robust cash reserve.
Insider MonkeyProtalix BioTherapeutics, Inc. (AMEX:PLX) Q1 2024 Earnings Call Transcript
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q1 2024 Earnings Call Transcript May 10, 2024 Protalix BioTherapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies and gentlemen, and welcome to the Protalix BioTherapeutics First Quarter 2024 Financial and Business […]
PR NewswireProtalix BioTherapeutics Reports First Quarter 2024 Financial and Business Results
Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended March 31, 2024, and provided a business and clinical update.
